K
Kanneboyina Nagaraju
Researcher at Binghamton University
Publications - 189
Citations - 9970
Kanneboyina Nagaraju is an academic researcher from Binghamton University. The author has contributed to research in topics: Duchenne muscular dystrophy & Skeletal muscle. The author has an hindex of 52, co-authored 181 publications receiving 8793 citations. Previous affiliations of Kanneboyina Nagaraju include Children's National Medical Center & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Overexpression of MHC Class I Heavy Chain Protein in Young Skeletal Muscle Leads to Severe Myositis : Implications for Juvenile Myositis
Charles K. Li,Paul Knopp,Halima Moncrieffe,Bhanu P. Singh,Sonia Shah,Kanneboyina Nagaraju,Hemlata Varsani,Bin Gao,Lucy R. Wedderburn +8 more
TL;DR: In this paper, a transgenic model of myositis induced by overexpression of MHC class I protein in skeletal muscle was adapted to investigate the effects of this protein overload on young muscle fibers, as compared with adult tissue.
Journal ArticleDOI
Modulation of disease severity in mice with targeted disruption of the acid α-glucosidase gene
TL;DR: In an attempt to reproduce the range of clinical manifestations of the human illness, null alleles at the acid α -glucosidase locus (GAA) are created with several gene targeting strategies and in each knockout strain, enzyme activity was completely abolished and glycogen accumulated at indistinguishable rates.
Journal ArticleDOI
Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy.
Eric P. Hoffman,Erica K.M. Reeves,Jesse M. Damsker,Kanneboyina Nagaraju,John M. McCall,Edward M. Connor,Kate Bushby +6 more
TL;DR: A new trial, FOR-DMD, aims to address a gap in knowledge in the area of "dissociative steroids," drugs that are able to better separate efficacy and side effects, providing a broader therapeutic window.
Journal ArticleDOI
Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy.
TL;DR: This review summarizes recent progress in exon-skipping therapy, targeting selected exons of prespliced mRNA for the dystrophin gene with antisense oligonucleotides, thereby restoring reading frames and discusses future perspectives with regard to human clinical trials.
Journal ArticleDOI
Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function.
Eric P. Hoffman,Benjamin D Schwartz,Laurel J Mengle-Gaw,Edward C. Smith,Diana Castro,Jean K. Mah,Craig M. McDonald,Nancy L. Kuntz,Richard S. Finkel,Michela Guglieri,Katharine Bushby,Mar Tulinius,Yoram Nevo,Monique M. Ryan,Richard D. Webster,Andrea L. Smith,Lauren P. Morgenroth,Antonio Arrieta,Maya Shimony,Catherine Siener,Mark Jaros,Phil Shale,John M. McCall,Kanneboyina Nagaraju,John N. van den Anker,Laurie S. Conklin,Avital Cnaan,Heather Gordish-Dressman,Jesse M. Damsker,Paula R. Clemens +29 more
TL;DR: This study provides Class IV evidence that for boys with DMD, vamorolone demonstrated possible efficacy compared to a natural history cohort of glucocorticoid-naive patients and appeared to be tolerated.